HANA Zahlen + Aussichten - 500 Beiträge pro Seite

[feuerfuss]

Donnerstag, 16. März 2006


Business Wire · Aktuelle Nachrichten · Archiv< zurück < · Druckversion
16.03.2006 10:08
Hana Biosciences Reports 2005 Results from Operations
Hana Biosciences (AMEX:HBX), a biopharmaceutical company focused on advancing cancer care, reported its results of operations for 2005 and the filing of its annual report on Form 10-K.

Hana reported a net loss of $10.0 million, or $0.57 per share for the year ended December 31, 2005, compared to a net loss of $7.3 million, or $0.80 per share, in 2004. Cash used in operations was 8.5 million in 2005. Hana ended 2005 with $17.0 million in cash and cash equivalents, compared to $6.6 million at the end of 2004. Increased investment in research and development, driven by the accelerated clinical development of its three product candidates, resulted in the additional expense throughout 2005.

"2005 was a milestone year in advancing our oncology product candidates and enhancing shareholder value," said Mark Ahn, President and CEO of Hana. "With our tightly focused business plan, experienced management team and deep commitment to advancing the care of cancer patients, we will strive to continue meeting and exceeding our objectives to deliver on the promise of emerging medical research."

Key Achievements in 2005

Hana achieved several important milestones in the development of its product portfolio during 2005:

-- Zensana(TM) (ondansetron oral spray), for the prevention of chemotherapy and radiation-induced, and post-operative nausea and vomiting, completed a pilot trial and first pivotal trial which demonstrated that an 8 mg dose of Zensana(TM) oral spray is statistically bioequivalent to the commercially available 8 mg ondansetron (Zofran(R)) tablet. Additionally, Zensana(TM) can be conveniently administered in multiple doses and was shown to have a similar safety profile to the ondansetron 8 mg tablet. Hana plans to submit a New Drug Application (NDA) to the FDA for Zensana(TM) in 2006, with a targeted commercial launch in 2007.

-- Talotrexin (PT-523) is a novel nonpolyglutamatable antifolate drug which has demonstrated enhanced antitumor activity in a broad spectrum of cancers by targeting DHFR to prevent DNA synthesis and inhibit tumor growth. Hana completed and reported results of a Phase I/II trial in NSCLC (non-small cell lung cancer), as well as initiated a Phase I/II study in ALL (acute lymphocytic leukemia).

-- IPdR is a novel, orally available, thymidine analogue and prodrug for IUdR, which demonstrated survival advantage in Phase II studies in anaplastic astrocytoma, a type of brain tumor. Hana initiated a Phase I clinical trial for IPdR for the treatment of colorectal, gastric, liver and pancreatic cancers.

In addition, Hana`s common shares were approved for listing on the American Stock Exchange (AMEX) in September 2005, trading under the symbol HBX.

Outlook for 2006

Hana previously announced the following milestones for 2006:

-- 1H 06: Announce results from Ph I clinical trials in NSCLC, ALL, and solid tumors

-- 1H 06: Initiate Talotrexin Ph II NSCLC, with potential interim results in Q4 06

-- 1H 06: Initiate Talotrexin Phase II trial in other tumor type

-- 1H 06: Submit Zensana(TM) NDA under 505(b)(2) registration, with potential US `07 market launch

-- 2H 06: Initiate additional Zensana(TM) clinical trials in chemotherapy-induced nausea and vomiting (CINV)

-- 2H 06: Initiate additional IPdR Phase I/II trial in glioblastoma multiforme (GBM) and/or neoadjuvant rectal cancer

-- 2H 06: Complete IPdR Ph I in gastric, colorectal, pancreatic and liver cancers

Hana Biosciences (Nachrichten) will host a teleconference to discuss the results presented above as well as an overview of 2006 goals at 4:30PM ET on Monday, March 20, 2006. Those interested in hearing management`s discussion may join the call by dialing [phone]. International participants may access the call by dialing [phone]. Participants may also access a live web-cast of the conference call through the Investor Relations section of Hana`s web site at http://www.hanabiosciences.com.

A replay will be available for three months following the call by dialing [phone] for domestic participants and [phone] for international participants and entering 286 for the playback account number and 196499 for the playback access code when prompted.

About Hana Biosciences, Inc.

Hana Biosciences, Inc. (AMEX:HBX) is a South San Francisco, CA-based biopharmaceutical company that acquires, develops, and commercializes innovative products to advance cancer care. The company is committed to creating value by building a world-class team, accelerating the development of lead product candidates, expanding its pipeline by being the alliance partner of choice, and nurturing a unique company culture. Additional information on Hana Biosciences can be found at www.hanabiosciences.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that could cause Hana`s actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Among other things, there can be no assurances that any of Hana`s development efforts relating to its product candidates will be successful. Other risks that may affect forward-looking information contained in this press release include the possibility of being unable to obtain regulatory approval of Hana`s product candidates, the risk that the results of clinical trials may not support Hana`s claims, Hana`s reliance on third-party researchers to develop its product candidates, and its lack of experience in developing pharmaceutical products. Additional risks are described in the company`s Annual Report on Form 10-K for the year ended Dec. 31, 2005. Hana assumes no obligation to update these statements, except as required by law.




Klicken Sie hier, um weitere aktuelle Nachrichten zum Unternehmen zu finden:

HANA BIOSCIENCES


Startseite · Nachrichten · Aktienkurse Top/Flop · Xetra-Orderbuch · Nachrichten-Watchlist · Ad-hoc Mitteilungen
Chartanalysen · Nachrichten Börsen · Aktien-Empfehlungen · Branchen · Medien · Aktien · Analysten-Ratings
Nachrichten-Archiv · Profil · Impressum · Presse · Mediadaten · Disclaimer · Umfragen
RSS-News von FinanzNachrichten.de kostenlos für Ihren Browser und Ihre Homepage
© 2000-2006 FinanzNachrichten.de: Aktie, Aktien, Aktienkurse, Nachrichten
FinanzNachrichten.de übernimmt keine Haftung für die Richtigkeit der Angaben!
Kurse: Lang & Schwarz Wertpapierhandel AG
Linktipps: Suchmaschine witch; Städteinfo; Lastminute Reisen; Preisvergleich kostenlos
Hotels Pensionen; Aktien Börse; Preisvergleich Test; Finanzen


08:26: Sixt Aktiengesellschaft
08:14: BOV AG
08:02: AT&S Austria Technologi
07:50: CeWe Color Holding AG
07:38: ComBOTS AG
15.03. ELMOS Semiconductor AG
15.03. LS telcom AG
15.03. IVU Traffic Technologie
15.03. VOGT electronic AG
15.03. ad pepper media Interna
15.03. NORDWEST Handel AG
15.03. Creaton AG
15.03. ESSANELLE HAIR GROUP AG
15.03. EVN AG
15.03. UZIN UTZ AG
15.03. CCR Logistics Systems A
15.03. Vivanco Gruppe AG
15.03. MAN AG
15.03. ARBOmedia AG
15.03. Westag&Getalit AG

Die SPD überlegt einen gesetztlichen Mindestlohn. Wie hoch sollte Ihrer Meinung nach ein unabhängig von der Tätigkeit ausbezahlter Mindestlohn sein?
- 5.000 Euro (7.800 Franken) pro Monat
- 4.000 Euro (6.240 Franken) pro Monat
- 3.000 Euro (4.680 Franken) pro Monat
- 2.000 Euro (3.120 Franken) pro Monat
- 1.500 Euro (2.340 Franken) pro Monat
- 1.000 Euro (1.560 Franken) pro Monat
- 500 Euro (780 Franken) pro Monat
- 0. Ich halte nichts von einem gesetzlich vorgeschriebenen Lohn. Der Staat sollte sich lieber nicht zu viel in die Wirtschaft einmischen.

Ergebnis/Archiv

[kafutznik]

Alles bestens ende des jahren 30 Euro

[kafutznik]

-- 1H 06: Submit Zensana(TM) NDA under 505(b)(2) registration, with potential US `07 market launch


Das ist was zählt erstmal die vorbereitungen für den Verkaufsstart laufen was meint ihr wo dann der Kurs hindonnert also alles bestens erstes Kurzziel 15 Euro in 6 Monaten minimum

[kafutznik]

HANA BIOSCIENCES INC Quick Quote: HBX 10.24 (Even)




Hana Biosciences to Present at the Bear Stearns' Bear Biotech West Coast Confab
3/22/2006

SOUTH SAN FRANCISCO, Calif., Mar 22, 2006 (BUSINESS WIRE) --
Hana Biosciences (AMEX:HBX) announced today that Mark Ahn, PhD, President & Chief Executive Officer, will present a company update at the Bear Biotech West Coast Confab on Thursday, March 23, at 12:30 p.m. PT in the Terrace Room at The Fairmont Hotel in San Francisco.

A live audio webcast of the presentation can be accessed on the investor relations page of the company's website, www.hanabiosciences.com. An audio replay of the presentation will also be available for 90 days after the conference.

About Hana Biosciences

Hana Biosciences, Inc. (AMEX:HBX) is a South San Francisco, CA-based biopharmaceutical company that acquires, develops, and commercializes innovative products to advance cancer care. The company is committed to creating value by building a world-class team, accelerating the development of lead product candidates, expanding its pipeline by being the alliance partner of choice, and nurturing a unique company culture. Additional information on Hana Biosciences can be found at www.hanabiosciences.com.

his press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that could cause Hana's actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Among other things, there can be no assurances that any of Hana's development efforts relating to its product candidates will be successful. Other risks that may affect forward-looking information contained in this press release include the possibility of being unable to obtain regulatory approval of Hana's product candidates, the risk that the results of clinical trials may not support Hana's claims, Hana's reliance on third-party researchers to develop its product candidates, and its lack of experience in developing pharmaceutical products. Additional risks are described in the company's Annual Report on Form 10-KSB for the year ended Dec. 31, 2004. Hana assumes no obligation to update these statements, except as required by law.

SOURCE: Hana Biosciences

Hana Biosciences John Iparraguirre, 650-588-6377 (Investors & Media) [e-mail] Fax: [phone]

Copyright Business Wire 2006

[willywilly]

Antwort auf Beitrag Nr.: 20.917.364 von kafutznik am 23.03.06 10:19:55

der am heißesten disskutierte shread HANA

falls es einen interessiert
American Bulls steht auf

BUY-IF

Bin ab heute bei Euch dabei und baue mir eine +
alternative Position auf

Willy

[cocolato]

Antwort auf Beitrag Nr.: 20.993.027 von willywilly am 29.03.06 16:16:26

Dann mal herzlich willkommen und viel Glück!!

[willywilly]

Antwort auf Beitrag Nr.: 21.000.057 von cocolato am 29.03.06 21:48:13

Hallo und guten Morgen,
der Tag beginnt mit einem
BUY
CONFIRMED

auf American Bulls
Willy

[kafutznik]

Antwort auf Beitrag Nr.: 21.021.496 von willywilly am 31.03.06 08:16:19

Perfekt kann schnell auf 12 Dollar laufen oder höher man weiß ja nie

[BrauchGeld]

Hana ist durch die neuen produkte sehr attraktiv geworden.
Ich hab mich aber trotzdem für Novadel entschieden Hana´s partner.

http://www.forbes.com/2006/03/30/hana-biosciences-0330market…

Hana's Potential Takeover Price Seen Near $20
Peter Kang, 03.30.06, 4:45 PM ET

RBC Capital Markets initiated coverage on Hana Biosciences with an "outperform" rating and said the specialty pharmaceutical company could benefit from better-than-expected sales of its cancer-related pain drug Zensana.

The company is expected to file for approval of the drug with federal health regulators in the second quarter of this year. Zensana is the spray form of leading anti-nausea drug Zofran, marketed by GlaxoSmithKline (nyse: GSK - news - people ).

"We believe Zensana could be preferred over current oral anti-nausea drugs because it is more convenient to take and delivers more drug faster," said RBC analyst David Bouchey.

The market for chemotherapy-induced nausea patients is estimated to be in excess of $1 billion, according to Bouchey, who predicts Hana will achieve peak Zensana sales of $150 million to $200 million.

"If Zensana can reach $100 million in sales in 2009 as we predict, then we believe Hana shares could appreciate by about 50% to our 12-month target price of $15."

In addition, to Zensana, Hana has five other pipeline candidates in various stages of development "which could provide positive news flow and upside potential to share price."

The RBC analyst said the company's management has done well in meeting its own goals and has made a number of well-structured licensing deals that makes a potential acquisition a real possibility.

"We believe having the only branded product in a rich market currently including multiple big pharma competitors could make Hana an attractive acquisition target to any competitor facing product life-cycle issues as well as any big pharma or big biotech with an oncology supportive care franchise," he said.

"If Hana is acquired after Zensana approval, we would expect a take-out price near $20 per share."

Bouchey forecasts FDA approval of Zensana by the early second quarter of 2007. The drug is expected to compete with similar anti-nausea treatments currently marketed by MGI Pharma (nasdaq: MOGN - news - people ), Roche and Sanofi-Aventis.

[kafutznik]

HANA BIOSCIENCES INC Quick Quote: HBX 10.15 (Even)




Hana Biosciences Initiates Talotrexin Phase II Clinical Trials in Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC)
3/31/2006

Completed Phase I Results to Be Presented at American Society of
Clinical Oncology (ASCO) Meeting to Be Held June 2-6, 2006 in Atlanta

SOUTH SAN FRANCISCO, Calif., Mar 31, 2006 (BUSINESS WIRE) --
Hana Biosciences (AMEX:HBX), a biopharmaceutical company focused on advancing cancer care, announced that the company initiated a multicenter, multinational Phase II clinical trial with Talotrexin (PT-523) in relapsed or refractory non-small cell lung cancer (NSCLC).

The primary objective of this Phase II portion of an ongoing Phase I/II open-label study is to demonstrate an improvement in overall survival. Secondary objectives are evaluation of safety, overall response rate, time to progression, and progression free survival. Relapsed or refractory NSCLC patients who have failed at least two lines of treatment including standard chemotherapy and/or an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor are eligible to enroll in the study. Patients who meet all eligibility criteria will receive Talotrexin on a 21-day cycle. Myelosuppresion and mucositis were the dose limiting toxicities of the Phase I portion of the trial that determined the recommended Phase II dose of Talotrexin in this setting. Updated clinical trial data will be presented during the 42nd Annual American Society of Clinical Oncology (ASCO) meeting in Atlanta, June 2-6, 2006.

"Advancing into Phase II is an exciting step forward in the development of Talotrexin as a potential therapy for heavily pre-treated non-small cell lung cancer patients," noted Greg Berk, MD, Chief Medical Officer and Senior Vice President, Hana Biosciences.

Jennifer Garst, MD, Assistant Professor of Medicine at Duke University, and an investigator on the trial commented, "Antifolates clearly have a role in the management of advanced non-small cell lung cancer. These preliminary data are encouraging and support taking this drug into the phase II setting."

Summary of Reported Interim Phase I Results in NSCLC

Previous positive interim Phase I data from this study evaluating single agent Talotrexin in relapsed or refractory advanced non-small cell lung cancer (NSCLC) was presented at the American Association for Cancer Research-National Cancer Institute-European Organisation for Research and Treatment of Cancer (AACR-NCI-EORTC) International Conference on Molecular Targets and Cancer Therapeutics in Philadelphia, Pennsylvania on November 16, 2005.

Talotrexin was administered as a 5-minute intravenous infusion (IV) on a 21-day cycle. Eligible patients with an ECOG performance status of 0-2 were administered increasing doses of Talotrexin during the study. Tumor response and disease progression relative to baseline was evaluated using the Response Evaluation Criteria in Solid Tumors (RECIST) methodology. Toxicity was graded using the National Cancer Institute Common Toxicity Criteria (NCI-CTC). At this interim analysis, 15 patients had received a total of 50 cycles of Talotrexin (median 3, range 1-8) at doses from 27 mg/m2 to 270 mg/m2 per cycle. Thirteen patients had evaluable CT scans, and all evaluated patients had failed previous platinum therapy. Talotrexin administered on this schedule as a single agent demonstrated acceptable tolerability and encouraging results in patients with relapsed or refractory NSCLC.

Interim results suggested:

-- Talotrexin is well tolerated over multiple cycles of therapy, with myelosuppresion and mucositis the dose limiting toxicities.

-- Clinical benefit in 67% or 10 (2 partial responses (PR) + 8 stable disease (SD)) of 15 treated patients was observed in patients after 2 or more cycles of Talotrexin. One patient who previously failed pemetrexed (Alimta(R)) has received 7 cycles of Talotrexin therapy. Median duration of PR and SD has not been reached to date.

About Talotrexin

Talotrexin is a novel nonpolyglutamatable antifolate drug which has demonstrated improved antitumor activity in a broad spectrum of preclinical cancer models by targeting dihydrofolate reductase (DHFR) to prevent DNA synthesis and inhibit tumor growth. Compared to methotrexate in preclinical studies, Talotrexin enters into cells up to 10-times more efficiently and demonstrates 10- to 100-fold more potency by overcoming resistance by remaining active in tumors by not requiring polyglutamation, and binds more tightly to its anti-tumor target DHFR which enhances efficacy. Talotrexin is currently being evaluated in two additional clinical trials: a Phase I trial in patients with solid tumors; and a Phase I/II multi-center trial in relapsed or refractory leukemias. Detailed information regarding these ongoing trials can be accessed at www.hanabiosciences.com. Additional trials in cervical and gastric cancers are planned.

About Non-Small Cell Lung Cancer (NSCLC)

According to the World Health Organization, there are more than 1.2 million cases worldwide of lung and bronchial cancer each year, causing approximately 1.1 million deaths annually. It is estimated that more than 173,000 people will be diagnosed with lung cancer in the United States in 2005. According to the National Cancer Institute, lung cancer is the single largest cause of cancer deaths in the United States and is responsible for nearly 30 percent of cancer deaths in this country. NSCLC is the most common form of the disease and accounts for more than 80 percent of all lung cancers. Despite recent therapeutic advances in NSCLC, the overall survival remains poor and there is a need for improved treatments.

About Hana Biosciences, Inc.

Hana Biosciences, Inc. (AMEX:HBX) is a South San Francisco, CA-based biopharmaceutical company that acquires, develops, and commercializes innovative products to advance cancer care. The company is committed to creating value by building a world-class team, accelerating the development of lead product candidates, expanding its pipeline by being the alliance partner of choice, and nurturing a unique company culture. Additional information on Hana Biosciences can be found at www.hanabiosciences.com.

his press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that could cause Hana's actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Among other things, there can be no assurances that any of Hana's development efforts relating to its product candidates will be successful. Other risks that may affect forward-looking information contained in this press release include the possibility of being unable to obtain regulatory approval of Hana's product candidates, the risk that the results of clinical trials may not support Hana's claims, Hana's reliance on third-party researchers to develop its product candidates, and its lack of experience in developing pharmaceutical products. Additional risks are described in the company's Annual Report on Form 10-K for the year ended Dec. 31, 2005. Hana assumes no obligation to update these statements, except as required by law.

SOURCE: Hana Biosciences, Inc.

Hana Biosciences, Inc. John Iparraguirre, 650-588-6377 (Investor & Media) Fax: [phone] [e-mail]

Copyright Business Wire 2006

[willywilly]

ich kam noch gar nicht dazu,
die Meldung zu übersetzen-
Der Kurs scheint aber DANKE
zu sagen
Ich auch
Willy

[mondialo]

Stocks >> NEWS


Hana Biosciences to Present at the CIBC World Markets Annual Biotechnology & Specialty Pharmaceutical Conference


SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--March 31, 2006--
Hana Biosciences (AMEX:HBX) announced today that Mark Ahn, Ph.D., President & Chief Executive Officer, will present a company update at the CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference on Tuesday, April 4, at 1:45 p.m. ET in Room 3.05 at The Millennium Broadway Hotel in New York City.

A live audio webcast of the presentation can be accessed on the investor relations page of the company's website, www.hanabiosciences.com. An audio replay of the presentation will also be available for 90 days after the conference.

About Hana Biosciences

Hana Biosciences, Inc. (AMEX:HBX) is a South San Francisco, CA-based biopharmaceutical company that acquires, develops, and commercializes innovative products to advance cancer care. The company is committed to creating value by building a world-class team, accelerating the development of lead product candidates, expanding its pipeline by being the alliance partner of choice, and nurturing a unique company culture. Additional information on Hana Biosciences can be found at www.hanabiosciences.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that could cause Hana's actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Among other things, there can be no assurances that any of Hana's development efforts relating to its product candidates will be successful. Other risks that may affect forward-looking information contained in this press release include the possibility of being unable to obtain regulatory approval of Hana's product candidates, the risk that the results of clinical trials may not support Hana's claims, Hana's reliance on third-party researchers to develop its product candidates, and its lack of experience in developing pharmaceutical products. Additional risks are described in the company's Annual Report on Form 10-KSB for the year ended Dec. 31, 2004. Hana assumes no obligation to update these statements, except as required by law.

Source: Hana Biosciences

[willywilly]

Irgendwie nervt es
Da bin ich investiert und dann
American Bulls setzt
SELL-IF
Mist, hätte ich nur später gekauft
Willy

[hcsf]

@willy

ist American Bulls deine einzige Entscheidungshilfe ?
Ich an deiner Stelle würde noch andere Seiten zu Rate ziehen,
zB. http://www.stockta.com/cgi-bin/analysis.pl?symb=HBX&num1=11&….

Es regnet im Moment von verschiedenen Analysten Kaufemphelungen mit Kurszielen bin 21 $. Long ist die Aktie ein hervorragendes Investment. Also dabei bleiben und die Nerven behalten.

Gruß

Hcsf

[Feivel65]

Die Empfehlung von American-Bulls ist nicht Gesetz. Die liegen oft genug falsch und das System berücksichtigt nur die Chartanalyse und nicht die Fundamentaldaten.

Desweiteren folgt auf ein SELL-IF bzw. SELL irgendwann wieder ein BUY-IF und BUY. Das ist ein ständiger Kreislauf. Insofern kannst Du locker bleiben. Man braucht eben Geduld. Ich war am Anfang auch mit HANA dick im Minus. Seit ich aber Geduld habe, hat sich das richtig für mich gelohnt und aus dem dicken Minus wurde irgendwann ein dickes Plus. Vertraue auf das Management. Das ist der größte Pluspunkt bei HANA.

[Rochelly]

Hallo Hana Gemeinde

wieso wurde ein neuer Thread zu Hana eröffnet. ??????
Unser bisheriger Thread war doch hervorragend mit aller
Faktenlage usw.

Rochelly

[Koboldzauber]

Global Biotech Investing Nr. 9 vom 15. Mai 2006:

NEW YORK – An den US-Börsen blieb der große Befreiungsschlag in der vergangenen Woche aus! Nicht wenige Marktteilnehmer hatten im Vorfeld der US-Notenbanksitzung letzten Mittwoch zwar auf eine weitere Zinserhöhung um 25 Basispunkte gesetzt, gleichzeitig aber ein klares Signal erwartet, dass die Phase der Zinserhöhungen zumindest vorübergehend vorbei sein könnte. Zumindest in einem Punkt hatte man Recht: Die Fed erhöhte die Leitzinsen zum 16. Mal in Folge, ließ sich aber die Tür für weitere Zinsschritte offen. Vor diesem Hintergrund konnten Standardwerte im Dow Jones angesichts starker Konjunkturdaten und Unternehmensnews zwar noch auf neue 6-Jahres-Hochs klettern, ein erhoffter Befreiungsschlag für die Indizes blieb damit aber vorerst aus – und mit ihm auch eine breit angelegte Erholung im Biotech-Sektor. Der ASE-Biotech-Index setzte in den vergangenen beiden Wochen mit schönen Tagesgewinnen zwar immer wieder einmal ein Ausrufezeichen, per saldo trat der Index im Bereich um 675 Punkte aber auf der Stelle. Dies eröffnet Anlegern weiterhin die Chance, zu ausgesprochen günstigen Kursen in einen auf Jahre hinaus boomenden Sektor zu investieren:

Die aktuelle Konsolidierung bei HANA BIOSCIENCES dürfte sich schon in wenigen Wochen als ausgezeichnete Nachkaufgelegenheit erweisen! Zuletzt hatte das Unternehmen ja bereits neue Forschungsdaten für den weltweit wichtigsten Krebskongress Anfang Juni angekündigt, in deren Mittelpunkt sicherlich der wichtigste Produktkandidat Talotrexin stehen dürfte. Bis dahin hat HANA BIOSCIENCES allerdings weitere News parat: So gab man vergangene Woche den erfolgreichen Abschluss des bereits vor wenigen Wochen gemeldeten Lizenzdeals bekannt: Damals hatte die Gesellschaft gleich 3 Wirkstoffe von der kanadischen Inex Pharmaceuticals übernommen und ihr Produktportfolio damit auf 6 Krebspräparate in klinischen Testreihen verdoppelt. Bei 2 Wirkstoffen sollen die klinischen Testphasen noch im laufenden Jahr gestartet werden, beim anderen Wirkstoff gleich im kommenden Jahr. Auch beim am weitesten fortgeschrittenen Medikament Zensana, das zur Behandlung von Übelkeit während einer Chemotherapie eingesetzt werden soll, läuft alles nach Plan: Nach ersten Erkenntnissen konnte das Medikament alle Ziele der klinischen Studien erreichen und steht mit einem für dieses Quartal geplanten Zulassungsantrag unmittelbar vor einer Vertriebsfreigabe durch die
FDA. HANA BIOSCIENCES rechnet im kommenden Jahr mit der Markteinführung. Stellen Sie sicher, dass Sie spätestens bis zum ASCO-Meeting eine Position in Ihrem Depot haben! (WKN A0E TGH)

[Koboldzauber]

Global Biotech Investing, Nr. 14 vom 31. Juli 2006

Was war im Berichtszeitraum bloß mit HANA BIOSCIENCES los? Im laufenden Monat verlor die Aktie von Kursen um USD 9 auf Kurse knapp oberhalb von EUR 6 zeitweise knapp 50%. Die Antwort: Rein gar nichts! Wir haben uns bei Händler direkt in New York umgehört, die uns gegenüber von einer Stop-Loss-Lawine berichteten, die mit dem Fall unter die wichtige Unterstützung bei USD 8 ausgelöst wurde. Neuigkeiten aus dem Unternehmen gab es indes keine,
zuletzt hatte HANA BIOSCIENCES Ende Juni einen Zulassungsantrag für das Medikament Zensana eingereicht, über den die FDA innerhalb einer 60-Tage-Frist entscheiden wird. Über unsere tagesaktuelle Infoline-Nr. 0900 / 1 77 69 90 haben wir in den vergangenen Wochen stets dazu geraten, an vorhandenen Positionen weiter festzuhalten und wurden für unsere Geduld belohnt: Von den im vergangenen Monat markierten Tiefs ging es zuletzt schon wieder über 20% nach oben und auch die Investmenthäuser geben der Aktie Rückendeckung: So liegt das durchschnittliche Kursziel aller Researchhäuser, die HANA BIOSCIENCES aktuell covern, bei USD 16.41 und damit deutlich mehr als 100% über den aktuellen Kursen, in der Spitze trauen die Analysten von C.E. Unterberg und Griffin Securities der Aktie den Sprung auf Kurse von USD 18 bzw. USD 19.50 zu! Wir würden bei HANA BIOSCIENCES weiterhin kein Stück aus der Hand geben, die Aktie zählt zu den spannendsten Investments im Krebsforschungssektor! (WKN A0E TGH, Kurs aktuell EUR 6.05, Reuters HNAB)

[Feivel65]

Antwort auf Beitrag Nr.: 23.199.179 von Koboldzauber am 29.07.06 10:54:42

Was?????? Innerhalb 60 Tagen??????? Das ist ja dann bald!!!